07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Agradil veralipride regulatory update

EMEA's CHMP recommended the withdrawal of marketing authorization for veralipride to treat hot flashes associated with menopause. The agency concluded that the dopamine blocker's benefits do not outweigh its risks, which include depression, anxiety, sleep...